TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Presentato dom 8 nov · 16:00 GMT-6LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia CareTutti gli studi Late-Breaking Science →

SUPERIOR

2026

Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial (SUPERIOR)

In patients with atrial fibrillation and hypertension undergoing catheter ablation, sacubitril/valsartan was associated with a lower rate of documented atrial arrhythmia recurrence at 12 months compared with valsartan.

Risultato

Recurrence of atrial arrhythmia after ablation (definition not public)
Differenza assoluta
10,3 punti

La differenza assoluta è derivata dai tassi di eventi.

Riportato inoltre: Clinic systolic blood pressure fell by about 10 mm Hg in both groups, with no significant difference in the reduction in 24-hour ambulatory blood pressure.

Pubblicazione originale
Sottotema
Upstream therapy
Disegno
Multicentre randomised controlled trial (per the programme) of sacubitril/valsartan for preventing AF recurrence after catheter ablation in hypertension
Arruolati
320 pazienti
Fonte
Zhang W. Presented at AHA Scientific Sessions 2026, 8 November. American Heart Association newsroom. Not yet published.

Discussione e critica

This randomised trial in 320 patients reports a lower rate of documented atrial arrhythmia recurrence with sacubitril/valsartan than with valsartan alone over 12 months after ablation. The release gives no hazard ratio, confidence interval, P value or safety data, so neither the precision nor the statistical significance of the difference can be judged. The trial was open label, although recurrences were adjudicated by a blinded team, and intermittent rhythm monitoring may have missed brief or asymptomatic episodes. Follow-up was limited to 12 months at three hospitals in China, and the findings come from an abstract that has not been peer reviewed.